Trial Profile
Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2014
Price :
$35
*
At a glance
- Drugs T 1210 (Primary) ; Olopatadine
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Laboratoires Thea
- 23 Apr 2014 New trial record